This is a summary of the European public assessment report (EPAR) for Zoledronic acid Teva. It explains how the Committee for Medicinal Products for Human Use (CHMP) assessed the medicine to reach its opinion in favour of granting a marketing authorisation and its recommendations on the conditions of use for Zoledronic acid Teva.
Therapeutic Indication
### Therapeutic indication Prevention of skeletal-related events and treatment of tumour-induced hypercalcaemia.
Therapeutic Area (MeSH)
ATC Code
M05BA08
ATC Item
zoledronic acid
Pharmacotherapeutic Group
Drugs for treatment of bone diseases
Active Substance (Summary)
INN / Common Names
| Substance | CAS | Monograph |
|---|---|---|
| zoledronic acid | N/A | 唑来膦酸 |
EMA Name
Zoledronic acid Teva
Medicine Name
Zoledronic acid Teva
Aliases
N/ANo risk management plan link.
